| Website | anacor.com |
| Category | BioTech |
| Phone | (650) 543-7500 |
| info@anacor.com | |
| Employees | 31 |
| Founded | 2000 |
| Description | Biotherapeutics Developer |
| TOTAL | $142M |
| FUNDING TOTAL | $142M |
| Series C, 5/05 Care Capital Venrock Red Abbey Venture Partners Aberdare Ventures Rho Capital Partners | $25M |
| Venture Round, 2/07 Schering | $50M |
| Series E, 1/09 GSK Venture Fund Rho Capital Partners Venrock Care Capital Aberdare Ventures Schering | $50M |
| Venture Round, 7/10 GSK Venture Fund | $15M |
| Grant, 11/10 United States Department of the Treasury | $1.5M |
Anacor Pharmaceuticals is a biopharmaceutical company that engages in developing small-molecule therapeutics from its boron chemistry platform. It focuses on developing topical applications of its compounds to treat fungal, bacterial, and inflammatory diseases.
The company’s primary product candidate, AN2690, is a novel topical antifungal for the treatment of toenail onychomycosis, a fungal infection of the nail and nail bed. It is also developing AN2728, an anti-inflammatory product candidate for the treatment of psoriasis; AN0128, a product candidate that has antibiotic and anti-inflammatory properties; and AN2718, which is in preclinical development for the topical treatment of vaginal candidiasis and tineapedis.
